- Issuer ticker
-
BIOA
- Reported as of
-
10 Jun 2026
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
4 source fields
- SEC form
-
4
- Accepted by SEC
-
12 Jun 2026, 16:31:53 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Dov A. Goldstein as attorney-in-fact
Key filing fact
Michael H. Davidson filed Form 4 for BioAge Labs, Inc. (BIOA) on 12 Jun 2026.
Key facts
- This page summarizes Michael H. Davidson's Form 4 filing for BioAge Labs, Inc. (BIOA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2026, 16:31.
Change
- Previous filing in this sequence was filed on 02 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001573785
Primary reporting owner
Davidson Michael H.
- Relationship
-
Director
- Address
- C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE
- Signature
- /s/ Dov A. Goldstein as attorney-in-fact
- Signature date
- 12 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +22,000
- Change %
- Price
-
$0.000000*
- Shares after
- 22,000
- Date
- 10 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,000
- Exercise price
- $15.48
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote